Home › Obesity › NCT07244458
Dietary Peanuts and Nutrition-Related Outcomes
Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial
Who can join
Ages 18 to 80 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been using semaglutide or tirzepatide for a clinical indication or at least 6 months Exclusion Criteria: * No use or contraindication to use of a GLP-1 RA * Known allergy to nuts * Pregnant or breastfeeding * Incarcerated
About the study
This study will look at how eating peanuts every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding peanuts to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating peanuts improves overall diet quality and health markers like tiredness and certain levels in blood.
What is being tested
- Peanuts (dietary supplement)
- Dual-energy X-ray absorptiometry (DEXA) scans (procedure)
Sponsor: Ian J. Neeland, MD · Participants: 64 · Started: Apr 20, 2026
Contact the study team
- Ian Neeland, MD · Phone: 216-844-5965
- Abigail Raffner, PhD, RD, LD · Phone: 216-368-0756
Official record on ClinicalTrials.gov — NCT07244458
Locations in the U.S.
| Ohio | University Hospitals Cleveland Medical Center, Clevland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.